Diorasis Therapeutics

Diorasis Therapeutics is a preclinical-stage company developing gene therapy for glaucoma. Our disease-modifying gene agnostic single intracameral injection gene therapy produces tissue of modified plasminogen activator (tPA) that normalizes trabecular meshwork outflow and IOP. Demonstrated significant efficacy :  Mice glaucoma model: outflow facility returned to normal, and IOP decreased to normal level after a single intracameral tPA GTx injection  Sheep glaucoma model: a single intracameral tPA-producing GTx injection dramatically decreased IOP to normal levels lasting until the end of 6 weeks experiment without any observed safety concerns  Normal mouse: no decrease in IOP (hypotony) after intracameral tPA GTx injection Currently, we are conducting tox and IND-enabling studies to file IND